Skip to main content
Top
Gepubliceerd in: Quality of Life Research 12/2018

05-09-2018

Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)

Auteurs: Loretta A. Williams, Meagan S. Whisenant, Tito R. Mendoza, Shireen Haq, Karen N. Keating, Brian Cuffel, Charles S. Cleeland

Gepubliceerd in: Quality of Life Research | Uitgave 12/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Malignant pleural mesothelioma (MPM) is an aggressive cancer of the lung pleura. The MD Anderson Symptom Inventory (MDASI) is a patient-reported outcome (PRO) measure of symptom burden, the combined impact of disease-related and treatment-related symptoms on functioning. Validated PRO measures may require modification for use in specific study populations. We sought to modify the MDASI for patients with MPM and create a fit-for-purpose symptom-burden measure for use in a clinical trial, according to US Food and Drug Administration guidance on PRO utilization to support labeling claims.

Methods

A literature review for MPM symptoms was conducted. Patients with MPM were qualitatively interviewed about experiences of disease and treatment. Descriptive analysis identified symptoms and interference with functioning to define MPM-related symptom burden. An expert panel rated the relevance of identified symptoms to patients with MPM. Patients who received the investigational drug in a previous Phase I study were interviewed for drug-specific symptoms.

Results

Literature review and interviews of 20 patients identified 31 MPM-related symptoms. A conceptual model of MPM-related symptom burden was developed. After expert-panel relevance review, five MPM-specific items and the 13 core MDASI symptoms met criteria for inclusion in a provisional MDASI-MPM for psychometric testing. Interviews with six patients identified six drug-specific symptoms; three were mentioned by multiple patients. Of these three, one was not in the core MDASI.

Conclusions

The MDASI-MPM has established content validity and, with the addition of one symptom item, is ready for psychometric testing as fit-for-purpose for a clinical trial of an investigational agent.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., et al. (2016). NCCN guidelines insights: Malignant pleural mesothelioma, Version 3.2016. Journal of the National Comprehensive Cancer Network, 14(7), 825–836.CrossRef Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., et al. (2016). NCCN guidelines insights: Malignant pleural mesothelioma, Version 3.2016. Journal of the National Comprehensive Cancer Network, 14(7), 825–836.CrossRef
2.
go back to reference Cheepsattayakorn, A., & Cheepsattayakorn, R. (2016). Malignant pleural mesothelioma: Occupational and non-occupational asbestos exposures. Journal of Lung, Pulmonary & Respiratory Research, 3(3), 00085.CrossRef Cheepsattayakorn, A., & Cheepsattayakorn, R. (2016). Malignant pleural mesothelioma: Occupational and non-occupational asbestos exposures. Journal of Lung, Pulmonary & Respiratory Research, 3(3), 00085.CrossRef
3.
go back to reference Peto, J., Hodgson, J. T., Matthews, F. E., & Jones, J. R. (1995). Continuing increase in mesothelioma mortality in Britain. Lancet, 345(8949), 535–539.CrossRef Peto, J., Hodgson, J. T., Matthews, F. E., & Jones, J. R. (1995). Continuing increase in mesothelioma mortality in Britain. Lancet, 345(8949), 535–539.CrossRef
4.
go back to reference Hollen, P. J., Gralla, R. J., Liepa, A. M., Symanowski, J. T., & Rusthoven, J. J. (2004). Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: Using the LCSS-meso conceptual model for validation. Cancer, 101(3), 587–595.CrossRef Hollen, P. J., Gralla, R. J., Liepa, A. M., Symanowski, J. T., & Rusthoven, J. J. (2004). Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: Using the LCSS-meso conceptual model for validation. Cancer, 101(3), 587–595.CrossRef
5.
go back to reference Ambrogi, V., Mineo, D., Gatti, A., Pompeo, E., & Mineo, T. C. (2009). Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma. Journal of Surgical Oncology, 100(3), 199–204.CrossRef Ambrogi, V., Mineo, D., Gatti, A., Pompeo, E., & Mineo, T. C. (2009). Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma. Journal of Surgical Oncology, 100(3), 199–204.CrossRef
6.
go back to reference Porter, M. E. (2010). What is value in health care? New England Journal of Medicine, 363(26), 2477–2481.CrossRef Porter, M. E. (2010). What is value in health care? New England Journal of Medicine, 363(26), 2477–2481.CrossRef
8.
go back to reference Lasch, K. E., Marquis, P., Vigneux, M., Abetz, L., Arnould, B., Bayliss, M., et al. (2010). PRO development: Rigorous qualitative research as the crucial foundation. Quality of Life Research, 19(8), 1087–1096.CrossRef Lasch, K. E., Marquis, P., Vigneux, M., Abetz, L., Arnould, B., Bayliss, M., et al. (2010). PRO development: Rigorous qualitative research as the crucial foundation. Quality of Life Research, 19(8), 1087–1096.CrossRef
9.
go back to reference Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., et al. (2011). Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1—eliciting concepts for a new PRO instrument. Value in Health, 14(8), 967–977.CrossRef Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., et al. (2011). Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1—eliciting concepts for a new PRO instrument. Value in Health, 14(8), 967–977.CrossRef
10.
go back to reference Rothman, M., Burke, L., Erickson, P., Leidy, N. K., Patrick, D. L., & Petrie, C. D. (2009). Use of existing patient-reported outcome (PRO) instruments and their modification: The ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value in Health, 12(8), 1075–1083.CrossRef Rothman, M., Burke, L., Erickson, P., Leidy, N. K., Patrick, D. L., & Petrie, C. D. (2009). Use of existing patient-reported outcome (PRO) instruments and their modification: The ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value in Health, 12(8), 1075–1083.CrossRef
11.
go back to reference Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., et al. (2000). Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer, 89(7), 1634–1646.CrossRef Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., et al. (2000). Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer, 89(7), 1634–1646.CrossRef
12.
go back to reference Cleeland, C. S. (2007). Symptom burden: Multiple symptoms and their impact as patient-reported outcomes. Journal of the National Cancer Institute. Monographs, 37, 16–21.CrossRef Cleeland, C. S. (2007). Symptom burden: Multiple symptoms and their impact as patient-reported outcomes. Journal of the National Cancer Institute. Monographs, 37, 16–21.CrossRef
13.
go back to reference Jones, D., Zhao, F., Fisch, M. J., Wagner, L. I., Patrick-Miller, L. J., Cleeland, C. S., et al. (2014). The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: Evidence from the symptom outcomes and practice patterns (SOAPP) data from the Eastern Cooperative Oncology Group. Clinical Genitourinary Cancer, 12(1), 41–49.CrossRef Jones, D., Zhao, F., Fisch, M. J., Wagner, L. I., Patrick-Miller, L. J., Cleeland, C. S., et al. (2014). The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: Evidence from the symptom outcomes and practice patterns (SOAPP) data from the Eastern Cooperative Oncology Group. Clinical Genitourinary Cancer, 12(1), 41–49.CrossRef
14.
go back to reference Mendoza, T. R., Zhao, F., Cleeland, C. S., Wagner, L. I., Patrick-Miller, L. J., & Fisch, M. J. (2013). The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: Evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group. Clinical Breast Cancer, 13(5), 325–334.CrossRef Mendoza, T. R., Zhao, F., Cleeland, C. S., Wagner, L. I., Patrick-Miller, L. J., & Fisch, M. J. (2013). The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: Evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group. Clinical Breast Cancer, 13(5), 325–334.CrossRef
15.
go back to reference Armstrong, T. S., Gning, I., Mendoza, T. R., Vera-Bolanos, E., Gilbert, M. R., Rhines, L. D., et al. (2010). Reliability and validity of the M. D. Anderson Symptom Inventory-spine tumor module. Journal of Neurosurgery: Spine, 12(4), 421–430.PubMed Armstrong, T. S., Gning, I., Mendoza, T. R., Vera-Bolanos, E., Gilbert, M. R., Rhines, L. D., et al. (2010). Reliability and validity of the M. D. Anderson Symptom Inventory-spine tumor module. Journal of Neurosurgery: Spine, 12(4), 421–430.PubMed
16.
go back to reference Armstrong, T. S., Mendoza, T., Gning, I., Coco, C., Cohen, M. Z., Eriksen, L., et al. (2006). Validation of the M.D. Anderson Symptom Inventory brain tumor module (MDASI-BT). Journal of Neuro-Oncology, 80(1), 27–35.CrossRef Armstrong, T. S., Mendoza, T., Gning, I., Coco, C., Cohen, M. Z., Eriksen, L., et al. (2006). Validation of the M.D. Anderson Symptom Inventory brain tumor module (MDASI-BT). Journal of Neuro-Oncology, 80(1), 27–35.CrossRef
17.
go back to reference Fadol, A., Mendoza, T., Gning, I., Kernicki, J., Symes, L., Cleeland, C. S., et al. (2008). Psychometric testing of the MDASI-HF: A symptom assessment instrument for patients with cancer and concurrent heart failure. Journal of Cardiac Failure, 14(6), 497–507.CrossRef Fadol, A., Mendoza, T., Gning, I., Kernicki, J., Symes, L., Cleeland, C. S., et al. (2008). Psychometric testing of the MDASI-HF: A symptom assessment instrument for patients with cancer and concurrent heart failure. Journal of Cardiac Failure, 14(6), 497–507.CrossRef
18.
go back to reference Gning, I., Trask, P. C., Mendoza, T. R., Harle, M. T., Gutierrez, K. A., Kitaka, S. A., et al. (2009). Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology, 76(1), 59–68.CrossRef Gning, I., Trask, P. C., Mendoza, T. R., Harle, M. T., Gutierrez, K. A., Kitaka, S. A., et al. (2009). Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology, 76(1), 59–68.CrossRef
19.
go back to reference Mendoza, T. R., Wang, X. S., Lu, C., Palos, G. R., Liao, Z., Mobley, G. M., et al. (2011). Measuring the symptom burden of lung cancer: The validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. The Oncologist, 16(2), 217–227.CrossRef Mendoza, T. R., Wang, X. S., Lu, C., Palos, G. R., Liao, Z., Mobley, G. M., et al. (2011). Measuring the symptom burden of lung cancer: The validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. The Oncologist, 16(2), 217–227.CrossRef
20.
go back to reference Rosenthal, D. I., Mendoza, T. R., Chambers, M. S., Asper, J. A., Gning, I., Kies, M. S., et al. (2007). Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module. Head and Neck, 29(10), 923–931.CrossRef Rosenthal, D. I., Mendoza, T. R., Chambers, M. S., Asper, J. A., Gning, I., Kies, M. S., et al. (2007). Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module. Head and Neck, 29(10), 923–931.CrossRef
21.
go back to reference Sailors, M. H., Bodurka, D. C., Gning, I., Ramondetta, L. M., Williams, L. A., Mendoza, T. R., et al. (2013). Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecologic Oncology, 130(2), 323–328.CrossRef Sailors, M. H., Bodurka, D. C., Gning, I., Ramondetta, L. M., Williams, L. A., Mendoza, T. R., et al. (2013). Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecologic Oncology, 130(2), 323–328.CrossRef
22.
go back to reference Wang, X. S., Williams, L. A., Eng, C., Mendoza, T. R., Shah, N. A., Kirkendoll, K. J., et al. (2010). Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer, 116(8), 2053–2063.CrossRef Wang, X. S., Williams, L. A., Eng, C., Mendoza, T. R., Shah, N. A., Kirkendoll, K. J., et al. (2010). Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer, 116(8), 2053–2063.CrossRef
23.
go back to reference Williams, L. A., Agarwal, S., Bodurka, D. C., Saleeba, A. K., Sun, C. C., & Cleeland, C. S. (2013). Capturing the patient’s experience: Using qualitative methods to develop a measure of patient-reported symptom burden: An example from ovarian cancer. Journal of Pain and Symptom Management, 46(6), 837–845.CrossRef Williams, L. A., Agarwal, S., Bodurka, D. C., Saleeba, A. K., Sun, C. C., & Cleeland, C. S. (2013). Capturing the patient’s experience: Using qualitative methods to develop a measure of patient-reported symptom burden: An example from ovarian cancer. Journal of Pain and Symptom Management, 46(6), 837–845.CrossRef
24.
go back to reference Cleeland, C. S., Zhao, F., Chang, V. T., Sloan, J. A., O’Mara, A. M., Gilman, P. B., et al. (2013). The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer, 119(24), 4333–4340.CrossRef Cleeland, C. S., Zhao, F., Chang, V. T., Sloan, J. A., O’Mara, A. M., Gilman, P. B., et al. (2013). The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer, 119(24), 4333–4340.CrossRef
25.
go back to reference Reeve, B. B., Mitchell, S. A., Dueck, A. C., Basch, E., Cella, D., Reilly, C. M., et al. (2014). Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. Journal of the National Cancer Institute, 106(7), 1–8.CrossRef Reeve, B. B., Mitchell, S. A., Dueck, A. C., Basch, E., Cella, D., Reilly, C. M., et al. (2014). Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. Journal of the National Cancer Institute, 106(7), 1–8.CrossRef
26.
go back to reference Aktas, A., Walsh, D., & Kirkova, J. (2015). The psychometric properties of cancer multisymptom assessment instruments: A clinical review. Supportive Care in Cancer, 23(7), 2189–2202.CrossRef Aktas, A., Walsh, D., & Kirkova, J. (2015). The psychometric properties of cancer multisymptom assessment instruments: A clinical review. Supportive Care in Cancer, 23(7), 2189–2202.CrossRef
27.
go back to reference Wang, X. S., Cleeland, C. S., Mendoza, T. R., Yun, Y. H., Wang, Y., Okuyama, T., et al. (2010). Impact of cultural and linguistic factors on symptom reporting by patients with cancer. Journal of the National Cancer Institute, 102(10), 732–738.CrossRef Wang, X. S., Cleeland, C. S., Mendoza, T. R., Yun, Y. H., Wang, Y., Okuyama, T., et al. (2010). Impact of cultural and linguistic factors on symptom reporting by patients with cancer. Journal of the National Cancer Institute, 102(10), 732–738.CrossRef
28.
go back to reference Gelhorn, H. L., Eremenco, S., Skalicky, A. M., Balantac, Z., Cimms, T., Halling, K., et al. (2017). Content validity and ePRO usability of the BPI-sf and “worst pain” item with pleural and peritoneal mesothelioma. Journal of Patient-Reported Outcomes, 2(1), 16.CrossRef Gelhorn, H. L., Eremenco, S., Skalicky, A. M., Balantac, Z., Cimms, T., Halling, K., et al. (2017). Content validity and ePRO usability of the BPI-sf and “worst pain” item with pleural and peritoneal mesothelioma. Journal of Patient-Reported Outcomes, 2(1), 16.CrossRef
30.
go back to reference Turner, R. R., Quittner, A. L., Parasuraman, B. M., Kallich, J. D., & Cleeland, C. S. (2007). Patient-reported outcomes: Instrument development and selection issues. Value in Health, 10(Suppl 2), S86–S93.CrossRef Turner, R. R., Quittner, A. L., Parasuraman, B. M., Kallich, J. D., & Cleeland, C. S. (2007). Patient-reported outcomes: Instrument development and selection issues. Value in Health, 10(Suppl 2), S86–S93.CrossRef
31.
go back to reference Parse, R. R., Coyne, A. B., & Smith, M. J. (1985). Nursing research: Qualitative methods. Bowie: Brady Communications. Parse, R. R., Coyne, A. B., & Smith, M. J. (1985). Nursing research: Qualitative methods. Bowie: Brady Communications.
32.
go back to reference Williams, L. A., Mendoza, T. R., Shi, Q., Wang, X. S., Haq, S., Ali, N. N., et al. (2016). Measuring treatment-induced peripheral neuropathy in patients with cancer: The treatment-induced Peripheral Neuropathy Scale (TNAS) [abstract]. Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) 2016 Annual Meeting, Adelaide, Australia, Jun 23–25, 2016. Supportive Care in Cancer 24(Suppl 1), S133. Abstract #eP152. Williams, L. A., Mendoza, T. R., Shi, Q., Wang, X. S., Haq, S., Ali, N. N., et al. (2016). Measuring treatment-induced peripheral neuropathy in patients with cancer: The treatment-induced Peripheral Neuropathy Scale (TNAS) [abstract]. Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) 2016 Annual Meeting, Adelaide, Australia, Jun 23–25, 2016. Supportive Care in Cancer 24(Suppl 1), S133. Abstract #eP152.
33.
go back to reference Williams, L. A., Garcia-Gonzalez, A., Aheneku, H. O., Cortes, J. E., Garcia-Manero, G., Kantarjian, H. M., et al. (2015) A patient-reported outcome measure for symptoms and symptom burden of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [abstract]. American Society of Hematology (ASH) 57th Annual Meeting, Orlando FL, Dec 5–9, 2015. Blood 126(23), 2094–2095. Abstract #2094. Williams, L. A., Garcia-Gonzalez, A., Aheneku, H. O., Cortes, J. E., Garcia-Manero, G., Kantarjian, H. M., et al. (2015) A patient-reported outcome measure for symptoms and symptom burden of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [abstract]. American Society of Hematology (ASH) 57th Annual Meeting, Orlando FL, Dec 5–9, 2015. Blood 126(23), 2094–2095. Abstract #2094.
34.
go back to reference Williams, L. A., Garcia Gonzalez, A. G., Ault, P., Mendoza, T. R., Sailors, M. L., Williams, J. L., et al. (2013). Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood, 122(5), 641–647.CrossRef Williams, L. A., Garcia Gonzalez, A. G., Ault, P., Mendoza, T. R., Sailors, M. L., Williams, J. L., et al. (2013). Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood, 122(5), 641–647.CrossRef
35.
go back to reference Williams, L. A., Couriel, D. R., Mendoza, T. R., McCarthy, P. L., Neumann, J. L., White, M. H., et al. (2010). A new measure of symptom burden in chronic graft-versus-host disease [abstract]. American Society for Blood and Marrow Transplantation 2010 BMT Tandem Meetings, Orlando FL. Biology of Blood and Marrow Transplantation, 16(2 Suppl 2), 24–28. S177. Abstract #60. Williams, L. A., Couriel, D. R., Mendoza, T. R., McCarthy, P. L., Neumann, J. L., White, M. H., et al. (2010). A new measure of symptom burden in chronic graft-versus-host disease [abstract]. American Society for Blood and Marrow Transplantation 2010 BMT Tandem Meetings, Orlando FL. Biology of Blood and Marrow Transplantation, 16(2 Suppl 2), 24–28. S177. Abstract #60.
36.
go back to reference Williams, L. A., Araujo, D. M., Mendoza, T. R., Sailors, M. L., Ali, N. N., Huang, F., et al. (2013). A new symptom measure in gastrointestinal stromal tumors [abstract]. American Society of Clinical Oncology 49th Annual Meeting, Chicago IL, May 31–Jun 4, 2013. Journal of Clinical Oncology, 31(15 Suppl), e17508. Abstract #e17508. Williams, L. A., Araujo, D. M., Mendoza, T. R., Sailors, M. L., Ali, N. N., Huang, F., et al. (2013). A new symptom measure in gastrointestinal stromal tumors [abstract]. American Society of Clinical Oncology 49th Annual Meeting, Chicago IL, May 31–Jun 4, 2013. Journal of Clinical Oncology, 31(15 Suppl), e17508. Abstract #e17508.
37.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRef Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRef
38.
go back to reference Nowak, A. K., Stockler, M. R., & Byrne, M. J. (2004). Assessing quality of life during chemotherapy for pleural mesothelioma: Feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. Journal of Clinical Oncology, 22(15), 3172–3180.CrossRef Nowak, A. K., Stockler, M. R., & Byrne, M. J. (2004). Assessing quality of life during chemotherapy for pleural mesothelioma: Feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. Journal of Clinical Oncology, 22(15), 3172–3180.CrossRef
39.
go back to reference Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. European Journal of Cancer, 30A(5), 635–642.CrossRef Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. European Journal of Cancer, 30A(5), 635–642.CrossRef
41.
go back to reference Clayson, H., Seymour, J., & Noble, B. (2005). Mesothelioma from the patient’s perspective. Hematology/Oncology Clinics of North America, 19(6), 1175–1190.CrossRef Clayson, H., Seymour, J., & Noble, B. (2005). Mesothelioma from the patient’s perspective. Hematology/Oncology Clinics of North America, 19(6), 1175–1190.CrossRef
Metagegevens
Titel
Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
Auteurs
Loretta A. Williams
Meagan S. Whisenant
Tito R. Mendoza
Shireen Haq
Karen N. Keating
Brian Cuffel
Charles S. Cleeland
Publicatiedatum
05-09-2018
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 12/2018
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-1982-5

Andere artikelen Uitgave 12/2018

Quality of Life Research 12/2018 Naar de uitgave